Program at a Glance

July 10th 18:00-18:10 Welcome Address AliceT. Shaw Hiroyuki Mano National Cancer Center Research Institute) AliceT. Shaw (Massachusethis General Hospital, Harvard Medical School) Fostive Lung Cancer School Turnor Heterogenety in ALI Postive Lung Cancer Center Research Institute) Turnor Heterogenety in ALI Postive Lung Cancer Center Research Institute) Turnor Heterogenety in ALI Postive Lung Cancer Center (Massachusethis General Hospital, Harvard Medical School) Turnor Heterogenety in ALI Postive Lung Cancer Center (Massachusethis General Hospital, Harvard Medical School) Turnor Heterogenety in ALI Postive Lung Cancer Center (Massachusethis General Hospital, Harvard Medical Postive Lung Cancer Center (Massachusethis General Hospital, Harvard Medical Postive Lung Cancer Center (Massachusethis General Hospital, Harvard Medical Postive Lung Cancer Center) Application of a High-through of Unknown Significance to Institute (Massachusethis General Hospital East) Advances in Targeted There School (Massachusethis General Hospital East) Advances in Targeted There in Lung Cancer Center Hospital East) Advances in Targeted There in Lung Cancer Center Hospital East) Advances in Targeted There in Lung Cancer Center (Massachusethis General Evaluation of Unknown Significance to Institute) Hiroyuki Aburatani (Massachusethis General Hospital	Date	Time	Session	Chairperson	Speaker	Title		
18:10-19:30 Keynote Lectures AliceT. Shaw Hiroyuki Mano National Cancer Center Center Center (Second: Medicine Platford (National Cancer Center) AliceT. Shaw (Messachusetts General Hospital, Harvard Medical School) 19:50-21:50 Welcome Party July 11th 330-1000 1. Personalized Medical Exhause the administrategies in lung cancer Alexander Dillon Rocing Cancer Center Research Institute) Application of a High-throug Functional Evaluation of Various Nignificance to Personalized Medical Cancer Center Research Institute) Application of a High-throug Functional Evaluation of Various Nignificance to Personalized Medical of Various Nignificance to Personalized Medical Profiles Alexander Dillon Research Institute) Advances in Targeted There Research Institute Personalized Medical Profiles Personalized Medica	July 10th	18:00-18:10		l.				
Massachusetts General Footbeel Footbee				AliceT. Shaw	(National Cancer Center	Genomic Medicine Platformin		
July 11th 8:30-10:00 1. Personalized treatment strategies in lung cancer Alexander Drillon (National Cancer Center Research Institute) Alexander Drillon (Nemorial Sloan Kettering Cancer Center Hospital East) Advances in Targeting Advances in Small Cell Lung Cancer Advances in Targeting Advances in Small Cell Lung Cancer Center Hospital East) Alexander Drillon (Nettonal Cancer Center Hospital East) Advances in Targeting Project Advances in Targeting Project Advances in Small Cell Lung Cancer Center Hospital East) Advances in Targeting Project Advances in Small Cell Lung Cancer Center Hospital East) Advances in Small Cell Lung Cancer Center Hospital East) Advances in Small Cell Lung Cancer Center Hospital East) Advances in Small Cell Lung Cancer Center Hospital East) Advances in Small Cell Lung Cancer Center Advances in Small Cell Lung Center Advances in Sm					(Massachusetts General Hospital, Harvard Medical	Evolution of Resistance and TumorHeterogeneity in ALK- Positive Lung Cancer		
trealment strategies in lung cancer Maiorial Cancer Centler Research Institute		19:50-21:50	Welcome Party					
Memorial Stoan Kettering Cancer Center)	July 11th	8:30-10:00	treatment strategies		(National Cancer Center	Application of a High-throughput Functional Evaluation of Variants of Unknown Significance to Personalized Medicine		
(National Cancer Center Hospital East) Cenomic Screening Project (LC SCRUM-Lappin for the Establishment of Precision Medicine in Lung Cancer					(Memorial Sloan Kettering	Advances inTargeted Therapy For Driver-Positive Subsets Of Non-Small Cell Lung Cancers		
10:20-11:50 2. Latest advances in small cell lung cancer and mesothelicma Charles M. Rudin (Memorial Sloan Kettering Cancer Center) Hiroyuki Aburatani (The University of Tokyo) Cancer Center C					(National Cancer Center	Establishment of Precision		
in small cell lung cancer and mesothelioma Hiroyuki Aburatani (Memorial Sloan Kettering Cancer Center) Hiroyuki Aburatani (The University of Tokyo) ShoutaroTsuji (Kanagawa Cancer Center Research Institute) 11:50-12:50 Lunch and Poster View 12:50-14:20 Poster Presentation 14:20-15:50 3. Targeting KRAS mutant lung cancer Hiroki Nagase Hiroki Nagase Hiromichi Ebi (Aichi Cancer Center Research Institute) 15:50-16:10 Break 16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer The University of Teves MD Anderson Cancer Center Research Institute, Chiba University) Takashi Takahashi (Nagoya University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vander		10:00-10:20	Break					
Comprehense Molecular (The University of Tokyo) Comprehense Molecular Analysis of Malignant Pleur Mesothelioma ShoutaroTsuji (Kanagawa Cancer Center Research Institute) Coexclopment of Precise Diagram (Kanagawa Cancer Center Research Institute) Coexclopment of Precise Diagram (Kanagawa Cancer Center Research Institute) Coexclopment of Precise Diagram (Kanagawa Cancer Center Research Institute) Coexclopment of Precise Diagram (Kanagawa Cancer Center Research Institute) Coexclopment of Kanagawa Cancer Center Research Institute, Chiba University) Coexclopment of Cancer Center Research Institute, Chiba University) Coexclopment of Cancer Center, Vanderbilt University Medical Center Medical Cen		10:20-11:50	in small cell lung cancer and		(Memorial Sloan Kettering	Latest Advances in Small Cell Lung Cancer		
Christine Lovly (Vanderbilt University) Takashi Takahashi (Nagoya University) Cancer Center (Nagoya University) Cancer (Nagoya Univer						Analysis of Malignant Pleural		
12:50-14:20 Poster Presentation 14:20-15:50 3.Targeting KRAS-mutant lung cancer Hiroki Nagase Hiroki Nagase (The University of Texes MD Anderson Cancer Center) Hiroki Nagase (Chiba Cancer Center Research Institute, Chiba University) 15:50-16:10 Break 16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer Christine Lovly Takashi Takahashi (Nagoya University)					(Kanagawa Cancer Center	Oevelopment of Precise Diagnosis with a New Mesothelioma Marker Sialylated HEG1		
14:20-15:50 3. Targeting KRAS-mutant lung cancer Hiroki Nagase Hiroki Nagase Hiroki Nagase (Chiba Cancer Center Research Institute) 15:50-16:10 Break 16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer (Christine Lovly Vanderbilt University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Ryohei Katayama (Cancer Chemotherapy Center, JFCR) Drug Repurposing: Overcor the Acquired Resistance wo Other Target Inhibitors		11:50-12:50	Lunch and Poster View					
mutant lung cancer Hiroki Nagase Hiromichi Ebi (Aichi Cancer Center Research Institute, Chiba University) 15:50-16:10 Break 16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer Christine Lovly (Vanderbilt University) Christine Lovly (Vanderbilt University) Christine Lovly (Vanderbilt University) Christine Lovly (Vanderbilt University) Responses in Subgroups of KRAS-Mutant Lung Adenocarcinoma Combination Therapies Targeting KRAS Mutant Lung Cancer Targeting the RAS Gene aga Cancer Cancer Cancer Christine Lovly (Nagoya University) Christine Lovly (Vanderbilt University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt University Medical Center Medical Center Vanderbilt University Medical Center Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt Vanderbilt		12:50-14:20	Poster Presentation					
(Aichi Cancer Center Research Institute) Hiroki Nagase (Chiba Cancer Center Research Institute, Chiba University) 15:50-16:10 Break 16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer Takashi Takahashi (Nagoya University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) Ryohei Katayama (Cancer Chemotherapy Center, JFCR) Takeshi Takahashi (Nagoya University) Overcoming Resistance to Mutant-Selective EGFR Inhibition in EGFR-mutant L Cancer Targeting KRAS Mutant Luricancer Targeting the RAS Gene aga (Cancer Cancer Targeting the RAS Mutant Luricancer Targeting the RAS Mutant Luricance Research Targeting the RAS Mutant Luricancher Targeting the RAS Matant Luricancher Targeting the RAS Mutant Luricancher Targeting the RAS Matant Lurica		14:20-15:50			(The University of Texas MD	Responses in Subgroups of KRAS-Mutant Lung		
(Chiba Cancer Center Research Institute, Chiba University) 15:50-16:10 Break 16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer Christine Lovly Takashi Takahashi (Nagoya University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) Ryohei Katayama (Cancer Chemotherapy Center, JFCR) Drug Repurposing: Overcom the Acquired Resistance woother Target Inhibitors 18:00-19:00 Meet-the Expert Evening (all participants)					(Aichi Cancer Center Research	Targeting KRAS Mutant Lung		
16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer Christine Lovly Takashi Takahashi (Nagoya University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) Ryohei Katayama (Cancer Chemotherapy Center, JFCR) Takashi Takahashi (Nagoya University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) Drug Repurposing: Overcom the Acquired Resistance woother Target Inhibitors 18:00-19:00 Meet-the Expert Evening (all participants)					(Chiba Cancer Center Research	Targeting the RASGene against Cancer		
resistance to targeted therapies in lung cancer Takashi Takahashi (Nagoya University) Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) Ryohei Katayama (Cancer Chemotherapy Center, JFCR) Overcoming Resistance to Mutant-Selective EGFR Inhibition in EGFR-mutant L Cancer Drug Repurposing: Overcomethe Acquired Resistance wing Other Target Inhibitors		15:50-16:10	Break					
in lung cancer (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) Ryohei Katayama (Cancer Chemotherapy Center, JFCR) Drug Repurposing: Overcor the Acquired Resistance wind Other Target Inhibitors 18:00-19:00 Meet-the Expert Evening (all participants)		16:10-17:40	resistance to targeted therapies		(Nagoya University)			
(Cancer Chemotherapy Center, JFCR) the Acquired Resistance wind JFCR) 18:00-19:00 Meet-the Expert Evening (all participants)					(Vanderbilt University Medical Center, Vanderbilt Ingram	to Mutant-Selective EGFR Inhibition in EGFR-mutant Lung		
					(Cancer Chemotherapy Center,	Drug Repurposing: Overcoming the Acquired Resistance with Other Target Inhibitors		
19:30-21:30 Banquet		18:00-19:00	Meet-the Expert Evening (all participants)					
		19:30-21:30	Banquet					

Date	Time	Session	Chairperson	Speaker	Title		
July 12th	8:30-10:00	5. Novel immunotherapy strategies: Beyond PD-1/PD-L1	Justin F.Gainor Hiroyoshi Nishikawa	Hiroyoshi Nishikawa (Research Institute/EPOC, National Cancer Center, Nagoya University)	Complexed Immune Suppressive Mechanisms In Tumor Microenvironment		
				Justin F. Gainor (Massachusetts General Hospital)	Emerging Immunotherapy Combinations in the Management of Non-Small Cell Lung Cancer		
				Koji Tarnada (Yamaguchi University)	Revolution of CAR-T Cell Technology to Develop Next-generation Cancer Immunotherapy		
ĺ	10:00-10:20	Break	·				
	10:20-11:50	6. Primary and acquired mechanisms of resistance to immunotherapies	Roy S. Herbst Heiichiro Udono	Kenji Chamoto (Kyoto University)	The Role of Fatty Acid Oxidation of T Cells in the Synergistic Effect With PD-1 Blockade		
				Heiichiro Udono (Okayama University)	Anti-diabetes Drug, Metformin, Drives Metabolic Reprogramming of Tumor Microenvironment, Leading to Inhibition of Tumor Growth		
				Roy S. Herbst (Yale Cancer Center/Yale School of Medicine/Smilow Cancer Hospital)	Primary and Acquired Mechanisms of Resistance to Immunotherapies		
	11:50-12:50	Lunch					
	12:50-14:20	7.Tumor heterogeneity and circulating tumor DNA	Maximilian Diehn Seiji Yano	Seiji Yano (Cancer Research Institute, Nano Life Science Institute, Kanazawa University)	Inter-organ Heterogeneity on Mechanisms of Targeted Drug Resistance-Central Nervous System(CNS) vs extra CNS-		
				Maximilian Diehn (Stanford University School of Medicine)	Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring		
				Tsukasa Kadota (National Cancer Center Research Institute, The Jikei University School of Medicine)	Circulating MicroRNAs as Biomarkers for Early Detection and Prediction of Immunotherapeutic Response in Lung Cancer Patients		
	14:20-14:40	Break					
	14:40-16:10	8.Tumor microenvironment and implications for treatment	Miguel F. Sanmamed Kohei Miyazono	Atsushi Enomoto	Heterogeneity of Cancer- Associated Fibroblasts and		
		and implications for	Kohei Miyazono	(Nagoya University)	its Significance inTumor Progression and Response to Therapies		
		and implications for	Kohei Miyazono	Miguel F. Sanrramed (Yale School of Medicine)	its Significance inTumor Progression and Responseto		
		and implications for	Kohei Miyazono	Miguel F. Sanrramed	its Significance inTumor Progression and Response to Therapies Modeling Patient-derived Lung Tumor Microenvironment To		
	16:10-16:20	and implications for	·	Miguel F. Sanrnamed (Yale School of Medicine) Kohei Miyazono	its Significance inTumor Progression and Response to Therapies Modeling Patient-derived Lung Tumor Microenvironment To Develop Immunotherapies Regulation of the Development of Lung Cancer by TGF-β		

 δ